Pharmaceutical industry 01

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/23

encourage image

There's no tags or description

Looks like no tags are added yet.

24 Terms

1
New cards

Drugs/therapeutic products

- Substances or biolo prods used to diagnose, prevent or treat disease

- 2 categories: Small-molecule drugs & Biological products (biologics)

<p>- Substances or biolo prods used to diagnose, prevent or treat disease </p><p>- 2 categories: Small-molecule drugs & Biological products (biologics)</p>
2
New cards

Small-molecule drugs

- Relatively low molecular weight

- Prod by chem synth

<p>- Relatively low molecular weight </p><p>- Prod by chem synth</p>
3
New cards

Biological products (biologics)

- Larger and/or structurally more complex products

- Prod using biolo systems

- Ex: vaccines

<p>- Larger and/or structurally more complex products </p><p>- Prod using biolo systems</p><p>- Ex: vaccines</p>
4
New cards

Innovator (research-based) pharma companies

- Research-intensive, invest heavily to discover & develop new molecular entities

- Very large size

- Ex: Pfizer

<p>- Research-intensive, invest heavily to discover & develop new molecular entities</p><p>- Very large size </p><p>- Ex: Pfizer</p>
5
New cards

Generic pharma companies

- Don't conduct og discovery or clinical development needed for a NME

- Enter market w generic alternatives after relevant patent & regulatory exclusivity periods expire

- R&D focuses on formulation development, manufacturing process, etc.

- Medium-large size

- Ex: Teva

<p>- Don't conduct og discovery or clinical development needed for a NME</p><p>- Enter market w generic alternatives after relevant patent & regulatory exclusivity periods expire</p><p>- R&D focuses on formulation development, manufacturing process, etc.</p><p>- Medium-large size </p><p>- Ex: Teva</p>
6
New cards

Biotechnology companies

- Develop innovative therapeutics & tech's using science

- Originate from academic discoveries, established co's

- Range from start-ups to multinational co's

- Partner or acquired by larger pharma co's

Ex: Amgen

<p>- Develop innovative therapeutics & tech's using science</p><p>- Originate from academic discoveries, established co's</p><p>- Range from start-ups to multinational co's </p><p>- Partner or acquired by larger pharma co's</p><p>Ex: Amgen</p>
7
New cards

Contract research organizations (CROs)

- Provide specialized services for pharma industry including specialty manufacturing, specialty chem synth, etc.

- Focus on niche research areas

- Range from specialized small CROs to large global org's

- Ex: Parexel

<p>- Provide specialized services for pharma industry including specialty manufacturing, specialty chem synth, etc. </p><p>- Focus on niche research areas</p><p>- Range from specialized small CROs to large global org's</p><p>- Ex: Parexel</p>
8
New cards

Drugs sold in Canada

- 1000's licensed prods: most are versions of other prods

- Drug product database: prod records (Health Canada)

- Compendium of pharma & specialities: data on molecular entities

9
New cards

Molecular entity

- Active chem responsible for the drug's pharmacological activity

- Ex: acetaminophen

<p>- Active chem responsible for the drug's pharmacological activity</p><p>- Ex: acetaminophen</p>
10
New cards

Drug product

Finished formulation containing the molecular entity & excipients (other ingredients)

<p>Finished formulation containing the molecular entity & excipients (other ingredients)</p>
11
New cards

Typical drug project progression

1. Idea/target identification

2. Discovery

3. Preclinical development (research)

4. Clinical development (trials)

5. Regulatory review & approval

6. Market & post-market

<p>1. Idea/target identification</p><p>2. Discovery</p><p>3. Preclinical development (research) </p><p>4. Clinical development (trials) </p><p>5. Regulatory review & approval</p><p>6. Market & post-market</p>
12
New cards

1. Idea/target identification (drug project progression)

- Identify a biolo threat, pathway, disease mech or therapeutic strat

- Project initiation & feasibility

<p>- Identify a biolo threat, pathway, disease mech or therapeutic strat</p><p>- Project initiation & feasibility</p>
13
New cards

2. Discovery (drug project progression)

- Identify & optimize promising compounds

- Select a drug candidate (NME) from an idea for further development

- 1-3 years

<p>- Identify & optimize promising compounds </p><p>- Select a drug candidate (NME) from an idea for further development</p><p>- 1-3 years</p>
14
New cards

3. Preclinical development (research) - drug project progression

- Labo & animal studies: pharmacology, safety, etc.

- Formulation & manufacturing-process development

- IND submitted to FDA to allow clinical investigation

- 1-2 years

<p>- Labo & animal studies: pharmacology, safety, etc.</p><p>- Formulation & manufacturing-process development</p><p>- IND submitted to FDA to allow clinical investigation </p><p>- 1-2 years</p>
15
New cards

4. Clinical development (trials) - drug project progression

- Evaluate safety, tolerability & dose

- Determine efficacy & characterize adverse effects

- Confirm efficacy & safety in large popu's

- NDA filed

- 1-5 years optimal, 5-7 avg

<p>- Evaluate safety, tolerability & dose</p><p>- Determine efficacy & characterize adverse effects</p><p>- Confirm efficacy & safety in large popu's</p><p>- NDA filed</p><p>- 1-5 years optimal, 5-7 avg</p>
16
New cards

5. Regulatory review & approval (drug project progression)

- Submit evidence on quality, safety & efficacy

- Reg. review by FDA/Health Canada

- Decision on marketing authorization

- 0.5-1.5 years

<p>- Submit evidence on quality, safety & efficacy</p><p>- Reg. review by FDA/Health Canada </p><p>- Decision on marketing authorization</p><p>- 0.5-1.5 years</p>
17
New cards

6. Market & post-market (drug project progression)

- Monitor safety & effectiveness after approval

- Detect rare/long-term adverse effects

- Investigate additional indications/uses

<p>- Monitor safety & effectiveness after approval </p><p>- Detect rare/long-term adverse effects </p><p>- Investigate additional indications/uses</p>
18
New cards

NME, IND and NDA abbreviation

- NME: Drug candidate / New Molecular Entity

- IND: Investigational New Drug

- NDA: New Drug Application

<p>- NME: Drug candidate / New Molecular Entity </p><p>- IND: Investigational New Drug</p><p>- NDA: New Drug Application</p>
19
New cards

Drug candidate (NME)

- Identified after 1-3 yrs of research

- Confidential structures & data

- FDA authorization thru an IND not needed to do labo studies

- Animal researched is subject to applicable requirements

20
New cards

Investigational new drug (IND) application

- Regulatory submission needed before IND's start clinical investigation

- Submitted to FDA before human clinical studies

- FDA determines if studies expose participants to unreasonable risk → may be placed on hold

- Contain confidential commercial & scientific info

<p>- Regulatory submission needed before IND's start clinical investigation</p><p>- Submitted to FDA before human clinical studies </p><p>- FDA determines if studies expose participants to unreasonable risk → may be placed on hold </p><p>- Contain confidential commercial & scientific info</p>
21
New cards

IND application contents

- Animal pharmacology & toxicology info

- Manufacturing/CMC info

- Investigator info

etc.

<p>- Animal pharmacology & toxicology info</p><p>- Manufacturing/CMC info</p><p>- Investigator info</p><p>etc.</p>
22
New cards

New drug application (NDA)

- Application to FDA for market approval

1. Safety of drug

2. Efficacy of drug: benefits outweight risks?

3. Appropriate labeling: instructions & warnings

4. Manufacturing methods: quality control, reproducible methods?

<p>- Application to FDA for market approval </p><p>1. Safety of drug</p><p>2. Efficacy of drug: benefits outweight risks?</p><p>3. Appropriate labeling: instructions & warnings</p><p>4. Manufacturing methods: quality control, reproducible methods?</p>
23
New cards

Abbreviated new drug application (ANDA)

- Application submitted to FDA for approval of a generic drug

- Excipients may differ

- Applicant demonstrates pharma equiv & bioequiv to reference listed drug

- Generic applicants don't repeat full animal & clinical efficacy to establish drug's safety & effectiveness

- Prod must meet manufacturing, quality & labeling rules

<p>- Application submitted to FDA for approval of a generic drug</p><p>- Excipients may differ</p><p>- Applicant demonstrates pharma equiv & bioequiv to reference listed drug</p><p>- Generic applicants don't repeat full animal & clinical efficacy to establish drug's safety & effectiveness</p><p>- Prod must meet manufacturing, quality & labeling rules</p>
24
New cards

ANDA: The proposed generic generally must have the same...

1. Active ingredient(s)

2. Strength

3. Dosage form

4. Route of administration

5. Conditions of use as the reference prod. Subject to exceptions

<p>1. Active ingredient(s)</p><p>2. Strength</p><p>3. Dosage form</p><p>4. Route of administration</p><p>5. Conditions of use as the reference prod. Subject to exceptions</p>